Cargando…
MicroRNAs as a possible biomarker in the treatment of multiple sclerosis
Multiple sclerosis (MS) is a demyelinating, autoimmune and inflammatory disease that affects the central nervous system (CNS) and is one of the leading causes of disability in young adults worldwide. There are different drugs for the treatment of MS that aim to modify the natural course of the disea...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685387/ https://www.ncbi.nlm.nih.gov/pubmed/36439971 http://dx.doi.org/10.1016/j.ibneur.2022.11.001 |
_version_ | 1784835493430558720 |
---|---|
author | Pérez, Moisés Manuel Gallardo Eisele, Solón Javier Garcés |
author_facet | Pérez, Moisés Manuel Gallardo Eisele, Solón Javier Garcés |
author_sort | Pérez, Moisés Manuel Gallardo |
collection | PubMed |
description | Multiple sclerosis (MS) is a demyelinating, autoimmune and inflammatory disease that affects the central nervous system (CNS) and is one of the leading causes of disability in young adults worldwide. There are different drugs for the treatment of MS that aim to modify the natural course of the disease and thus slow its progression. This group of drugs is known as disease modifying therapy (DMT). To evaluate the effectiveness of these drugs, mainly clinical and MRI parameters are used. In recent years, different studies have emerged that propose the use of biomarkers to improve the evaluation of the effectiveness of DMT and to provide individualized therapy. MicroRNAs (miRNAs) are part of these biomarkers that have been proposed both for their wide availability in different tissues and body fluids and for their possible involvement in different biological processes. In this review we briefly discuss the mechanisms of action of drugs available for the treatment of MS, as well as recent findings on the expression levels of different miRNAs in MS patients under treatment with DMT. |
format | Online Article Text |
id | pubmed-9685387 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-96853872022-11-25 MicroRNAs as a possible biomarker in the treatment of multiple sclerosis Pérez, Moisés Manuel Gallardo Eisele, Solón Javier Garcés IBRO Neurosci Rep Article Multiple sclerosis (MS) is a demyelinating, autoimmune and inflammatory disease that affects the central nervous system (CNS) and is one of the leading causes of disability in young adults worldwide. There are different drugs for the treatment of MS that aim to modify the natural course of the disease and thus slow its progression. This group of drugs is known as disease modifying therapy (DMT). To evaluate the effectiveness of these drugs, mainly clinical and MRI parameters are used. In recent years, different studies have emerged that propose the use of biomarkers to improve the evaluation of the effectiveness of DMT and to provide individualized therapy. MicroRNAs (miRNAs) are part of these biomarkers that have been proposed both for their wide availability in different tissues and body fluids and for their possible involvement in different biological processes. In this review we briefly discuss the mechanisms of action of drugs available for the treatment of MS, as well as recent findings on the expression levels of different miRNAs in MS patients under treatment with DMT. Elsevier 2022-11-07 /pmc/articles/PMC9685387/ /pubmed/36439971 http://dx.doi.org/10.1016/j.ibneur.2022.11.001 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Pérez, Moisés Manuel Gallardo Eisele, Solón Javier Garcés MicroRNAs as a possible biomarker in the treatment of multiple sclerosis |
title | MicroRNAs as a possible biomarker in the treatment of multiple sclerosis |
title_full | MicroRNAs as a possible biomarker in the treatment of multiple sclerosis |
title_fullStr | MicroRNAs as a possible biomarker in the treatment of multiple sclerosis |
title_full_unstemmed | MicroRNAs as a possible biomarker in the treatment of multiple sclerosis |
title_short | MicroRNAs as a possible biomarker in the treatment of multiple sclerosis |
title_sort | micrornas as a possible biomarker in the treatment of multiple sclerosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685387/ https://www.ncbi.nlm.nih.gov/pubmed/36439971 http://dx.doi.org/10.1016/j.ibneur.2022.11.001 |
work_keys_str_mv | AT perezmoisesmanuelgallardo micrornasasapossiblebiomarkerinthetreatmentofmultiplesclerosis AT eiselesolonjaviergarces micrornasasapossiblebiomarkerinthetreatmentofmultiplesclerosis |